# Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

> **NCT04908956** · PHASE2 · TERMINATED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 6 (actual)

## Conditions studied

- NSCLC Stage IV
- EGFR Gene Mutation

## Interventions

- **DRUG:** Osimertinib
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT04908956
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-04
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-02-29
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The trial struggled with low activation due to the COVID pandemic. The Steering Committee took the decision to close the accrual in the STEREO trial as of 31 October 2023. It is important to note that no safety concerns have led to this decision.
- **Last updated:** 2024-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908956, "Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04908956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*